🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

8,395 results for “La” Clear

  1. RSV MAT

    GlaxoSmithKline

    Respiratory Syncytial Virus Infections

    phase 3 mab terminated

    1 trial

  2. Rabipur Pulver und Lösungsmittel zur Herstellung einer Injektionslösung in Fertigspritze Tollwutvirus (inaktiviert, Stamm Flury LEP)

    The George Institute

    Rabies infection/prophylaxis

    phase 3 small molecule active

    1 trial

  3. Raloxifene - Usual

    Lxo Ireland Designated Activity Company

    Breast Cancer

    phase 3 small molecule active

    1 trial

  4. Ramelteon

    Takeda

    Balance

    phase 3 small molecule completed

    1 trial

  5. Ramelteon SL

    Takeda

    Bipolar Disorder

    phase 3 small molecule terminated

    1 trial

  6. Ramelteon SL (Dose 1)

    Takeda

    Bipolar Disorder

    phase 3 small molecule terminated

    1 trial

  7. Ramelteon and Placebo (9 possible combinations total)

    Takeda

    Chronic Insomnia

    phase 3 small molecule completed

    1 trial

  8. Ramosetron

    Astellas Pharma Inc

    Vomiting

    phase 3 small molecule completed

    1 trial

  9. Randomized control trial comparison between intra-articular infiltrations of PRP, MFAT, and PRP-MFAT in the treatment of symptomatic knee osteoarthritis.

    ISTA Pharma Limited

    knee osteoarthritis

    phase 3 other active

    1 trial

  10. Randomized, double-blind, Phase 3 study comparing efficacy and safety of frexalimab (SAR441344) to teriflunomide in adult participants with relapsing forms of multiple sclerosis

    Sanofi-aventis Healthcare Pty Ltd

    multiple sclerosis

    phase 3 other active

    1 trial

  11. Randomized, open-label, Phase 3 study of SAR408701 versus docetaxel in previously treated, metastatic nonsquamous, non-small-cell lung cancer patients with CEACAM5-positive tumors

    Sanofi-aventis Healthcare Pty Ltd

    Non-small cell lung cancer metastatic

    phase 3 other active

    1 trial

  12. Ranibizumab

    Hoffmann-La Roche

    Neovascular Age-related Macular Degeneration (nAMD)

    phase 3 small molecule active

    1 trial

  13. Ranibizumab

    Regeneron UK Limited

    Macular Degeneration

    phase 3 small molecule completed

    2 trials

  14. Reagila 1.5 mg hard capsules, For the purpose of the clinical study a placebo formulation was prepared using the same white hard gelatine capsule shell., Reagila 3 mg hard capsules, Cariprazine 0.5 mg capsules, hard, Reagila 4.5 mg hard capsules

    Gedeon Richter Plc.

    Adolescent Patients (13 to 17 years of age) with Schizophrenia

    phase 3 small molecule active

    1 trial

  15. Realgar-Indigo naturalis formula

    The First People's Hospital of Lianyungang

    Acute Promyelocytic Leukemia

    phase 3 small molecule active

    1 trial

  16. Reblozyl 75 mg powder for solution for injection, Reblozyl 25 mg powder for solution for injection

    Celgene Europe Limited

    Myelodysplastic syndrome

    phase 3 small molecule active

    1 trial

  17. Reblozyl 75 mg powder for solution for injection, Reblozyl 25 mg powder for solution for injection

    Celgene Europe Limited

    myelodysplastic syndrome (MDS); beta (β)-thalassemia (THAL); myelofibrosis (MF)

    phase 3 small molecule active

    1 trial

  18. Recombinant Antihemophilic Factor Manufactured and Formulated without Added Human or Animal Proteins (rAHF-PFM)

    Takeda

    Hemophilia A

    phase 3 mab completed

    1 trial

  19. Recombinant Factor VIII (BAY81-8973)

    Bayer HealthCare AG

    Blood Coagulation Disorders

    phase 3 mab completed

    1 trial

  20. Recombinant Human VEGF Receptor-Fc Fusion Protein

    Biotech Pharmaceutical Co.,

    Neovascular Age-related Macular Degeneration

    phase 3 mab completed

    1 trial

  21. Recombinant antihemophilic factor, plasma/albumin-free method (rAHF-PFM)

    Takeda

    Hemophilia A

    phase 3 mab terminated

    1 trial

  22. Reducing Antibiotics treatment duration

    United Therapeutics Europe Ltd

    Ventilator Associated Pneumonia

    phase 3 small molecule completed

    1 trial

  23. Regorafenib (BAY73-4506)

    Bayer HealthCare AG

    Colorectal Neoplasms

    phase 3 small molecule completed

    1 trial

  24. Relacorilant

    CORCEPT THERAPEUTICS INC

    Hypercortisolism

    phase 3 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources